Company Overview
Xeris Biopharma Holdings, Inc. operates as a commercial-stage biopharmaceutical entity focused on developing and commercializing therapies for chronic endocrine and neurological diseases, with a specific offering of Gvoke, a ready-to-use liquid-stable glucagon designed for the treatment of severe hypoglycemia in pediatric patients. The company functions within the broader Healthcare sector and specifically within the Biotechnology industry, positioning itself to address specialized medical needs through proprietary therapeutic solutions. As of the latest data, Xeris holds a market capitalization of $950.96M and reports annual revenue of $291.84M, supported by an employee base of 435 individuals. These financial figures indicate that Xeris has established a significant operational footprint in the biotechnology landscape, suggesting a substantial scale for a commercial-stage company that is actively translating its research and development efforts into marketable products within the Illinois-based market.
Financial Health
The company's financial performance over the trailing twelve months demonstrates a revenue generation of $291.84M with a net income of $554,000 and an EBITDA of $37.05M, revealing a distinct gap between top-line revenue and bottom-line profit that highlights a cost structure heavily influenced by research and development expenses or other operating costs. Despite the low net income, the company maintains robust free cash flow of $25.97M, which provides significant financial flexibility to fund ongoing operations, invest in pipeline advancements, or manage working capital without immediate reliance on external financing. Profitability analysis shows a gross margin of 85.4%, indicating high efficiency in production and cost of goods sold relative to revenue, while an operating margin of 19.5% suggests effective control over general and administrative expenses. However, the profit margin stands at 0.2%, reflecting the intense competition and high investment environment typical of the biotechnology sector where profitability is often sacrificed for long-term growth potential. On the balance sheet, Xeris holds $111.04M in cash against $258.10M in debt, resulting in a debt-to-equity ratio of 1885.44, which characterizes the balance sheet as highly leveraged given the substantial debt load relative to equity. Liquidity is supported by a current ratio of 2.19, indicating that the company possesses more than double the current assets necessary to cover its short-term liabilities, thereby ensuring adequate short-term liquidity. Return metrics show a return on assets of 4.4% and a return on equity listed as N/A, revealing that management's effectiveness in generating returns on the asset base is moderate, while the N/A status for ROE likely stems from the specific accounting treatment of the company's equity or capital structure.
Valuation Assessment
Valuation metrics for Xeris include a trailing P/E ratio that is listed as N/A due to the minimal net income, while a forward P/E of 14.89 suggests that the market expects a significant improvement in earnings trajectory or a shift in valuation methodology based on projected future performance. The price-to-book ratio stands at 67.26, indicating a substantial market premium over the book value that reflects the high intangible value of the company's intellectual property and future drug pipeline rather than current tangible assets. Alternative valuation measures such as a price-to-sales ratio of 3.26 and an EV/EBITDA of 29.29 suggest that the market values the company primarily on its revenue generation and earnings before interest, taxes, depreciation, and amortization, rather than traditional earnings multiples. The stock has traded between a 52-week high of $10.08 and a 52-week low of $3.81, meaning the current trading price sits at a position that fluctuates significantly within this established range depending on market sentiment. The beta value of 0.97 indicates that the stock's price volatility is closely aligned with the broader market, moving at a pace that is neither significantly more nor less volatile than the overall market index.
Growth & Income
Revenue growth is reported at 42.8% year-over-year, demonstrating a strong expansion in sales, while earnings growth is listed as N/A, implying that earnings are not yet growing at a comparable rate to revenue due to the low absolute net income figure. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests its earnings directly into growth initiatives, research, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is typical for commercial-stage biopharmaceutical companies that prioritize scaling their product portfolios and expanding market penetration over returning capital to investors. The overall growth and income profile is defined by rapid revenue expansion funded by strong free cash flow, with the company foregoing current income distribution to fuel long-term development in the endocrine and neurological disease sectors.